etira
  • Home
  • Our Company
  • Our Science
  • Clinical Trial
  • Our Pipeline
  • Our Team
  • News
  • Contact
  • Menu Menu
  • LinkedIn
  • Home
  • Our Company
  • Our Science
  • Clinical Trial
  • Our Pipeline
  • Our Team
  • News
  • Contact

Slide Our Mission
is more
than Remission
We are intensely focused on developing effective therapies that overcome the single largest barrier to long term, durable cancer therapy: Tumor Heterogeneity The greatest challenge in
cancer therapy.

Your Dream Home Our
Vision
We are committed to the development of next-generation therapeutics to overcome untreatable cancers and enable futures for our patients.

We believe that our pipelines hold the promise of tomorrow’s treatments.


Your Dream Home Our name draws inspiration from Atira, the earth mother in Native American Pawnee culture. Esteemed for her nurturing and protective qualities, Atira symbolizes the essence of life that springs from the earth. Atira also represents “prayer” in ancient Hebrew culture. The dual etymology of our name symbolizes our mission to provide hope for patients with advanced cancers. Etira
Origin

Our Vision Our
Company
As scientists we are whole-heartedly committed to finding potential treatments that prolong lives or provide the hope needed to face another day.

As a company, we are united in this pursuit. And will never give up.

House Layout We are etira.
and to us,
life is
absolutely
priceless.

 

etira logo

 

Where to find us

Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247

Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247

Scroll to top
Inclusion criteria:
  • Patients must be at least 18 years of age at the time of signing the informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
  • Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Adequate baseline organ function and hematologic function
  • Life expectancy >3 months
Exclusion criteria
  • Systemic anti-cancer therapy within 4 weeks of first dose of study drug
  • Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
  • Uncontrolled intercurrent illnesses
  • Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.